CP-242 Bevacizumab in glioblastoma or anaplasic astrocytoma: effectiveness, safety and cost effectiveness analysis

CP-242 Bevacizumab in glioblastoma or anaplasic astrocytoma: effectiveness, safety and cost effectiveness analysis

This abstract was published in error and withdrawn at the author’s request.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of hospital pharmacy. Science and practice 2017-03, Vol.24 (Suppl 1), p.A109-A109
Hauptverfasser: Sanchez, MDP Vicente, Cano, JM Cano, Serrano, R Perez, Sereno, MT Franco, Pardo, MDM Alañon, Yañez, M Mallol, Giménez, IDLD Benet, Martínez, M Rodríguez
Format: Artikel
Sprache:eng
Schlagworte:
Brain cancer
Monoclonal antibodies
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This abstract was published in error and withdrawn at the author’s request.
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2017-000640.240